Merck obtains right to experimental Ebola vaccine By: MarketWatch November 24, 2014 at 11:23 AM EST NewLink Genetics to receive $30 million upfront, plus an additional $20 million. Read More >> Related Stocks: Johnson & Johnson Merck & Co Newlink Genetics Cor